Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer

Publication Name: International Journal of Molecular Medicine

Author(s): Heidrun Gevensleben, Uwe-Jochen Gohring, Reinhard Buttner. Lukas C. Heukamp, Georg Kunz, Thomas Dimpfl, Christian Jackisch, Olaf Ortmann, Ute-Susann Albert, Richard Bender, Femke De Snoo, Oscar Krijgsman, Annuska M. Glas

The 70-gene expression profile MammaPrint is a powerful prognostic indicator for disease outcome in breast cancer patients with improved prediction of recurrence risk compared to currently used guidelines. The microarray-based test TargetPrint further provides reliable, quantitative assessment of mRNA expression … Continued

Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population

Publication Name: Japanese Journal of Clinical Oncology

Author(s): Makoto Ishitobi, Teodora Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska Glas, Ellen van Lienen, Hideo Inaji Laura van’t Veer and Kikuya Kato

Objective: van’t Veer and colleagues developed a 70-gene prognosis profile known as MammaPrint to identify breast cancer patients who were at low risk of developing metastases. We evaluated the prognostic value of the 70-gene MammaPrint profile in Japanese women with … Continued

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

Publication Name: European Journal of Cancer

Author(s): Valesca Retel, MA Joore, WH van Harten

Background: The 70-gene signature (MammaPrint) is a prognostic test used to guide adjuvant treatment decisions in patients with node-negative breast cancer. In order to decide upon its use, a systematic comparative analysis of the effects of the 70-gene signature,the Saint … Continued

Use of a genomic test (MammaPrint) in daily clinical practice to assist in risk stratification of young breast cancer patients

Publication Name: Archives of Gynecology and Obstetrics

Author(s): Georg Kunz

Purpose: Breast cancer as a heterogeneous disease demands reliable tools in order to identify those patients who most likely will benefit from receiving adjuvant treatment, such as chemotherapy. MATERIALS AND METHODS: The MammaPrint test was established on the basis of … Continued

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Publication Name: Breast Cancer Research and Treatment

Author(s): Michael Knauer, Stella Mook, Emiel J. T. Rutgers, Richard A. Bender, Michael Hauptmann, Marc J. van de Vijver, Rutger H. T. Koornstra, Jolien M. Bueno-de-Mesquita, Sabine C. Linn, Laura J. van ’t Veer

Multigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value of the 70-gene MammaPrint signature for chemotherapy (CT) benefit in addition to endocrine therapy (ET) from pooled … Continued

MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer.

Publication Name: Expert Opinion Medical Diagnostics

Author(s): Phillipe L Bedard, Stella Mook, Martine J Piccart-Gebhart, Emiel T Rutgers, Laura J van ‘t Veer and Fatima Cardoso

Background: Over the past few years, a variety of multigene expression profiles have been developed to improve prognostication for early stage breast cancer and reduce overtreatment with chemotherapy. MammaPrint is the only test cleared by the US Food and Drug … Continued

Gene Expression profiling: Decoding breast cancer.

Publication Name: Surgical Oncology

Author(s): deSnoo F , Bender R, Glas G and Rutgers E

Gene expression assays that are used in daily clinical practice for treating early breast cancer patients have been introduced in the clinic only recently. This review discusses the development of these arrays, summarizes the validation of those that are commercially … Continued

Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer

Publication Name: Clinical Cancer Research

Author(s): Paul Roepman, Hugo M. Horlings, Oscar Krijgsman, Marleen Kok, Jolien M. Bueno-de-Mesquita, Richard Bender, Sabine C. Linn, Annuska M. Glas and Marc J. van de Vijver

Purpose: The level of estrogen receptor (ER), progesterone receptor (PR), and HER2 aids in the determination of prognosis and treatment of breast cancer. Immunohistochemistry is currently the predominant method for assessment, but differences in methods and interpretation can substantially affect … Continued

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Publication Name: Annals of Oncology

Author(s): Mook S, Schmidt MK, Weigelt B

Background: The majority of breast cancer patients are postmenopausal women who are increasingly being offered adjuvant chemotherapy. Since the beneficial effect of chemotherapy in postmenopausal patients predominantly occurs in the first 5 years after diagnosis, a prognostic marker for early … Continued

Validation of 70-gene prognosis signature in node-negative breast cancer

Publication Name: Breast Cancer Research & Treatment

Author(s): Bueno-de-Mesquita JM, Keijzer R, Linn SC

Purpose: The 70-gene prognosis signature (van’t Veer et al., Nature 415(6871):530–536, 2002) may improve the selection of lymph node-negative breast cancer patients for adjuvant systemic therapy. Optimal validation of prognostic classifiers is of great importance and we therefore wished to … Continued